Direct Thrombin Inhibition in Extracorporeal Membrane Oxygenation

Janos Geli, Massimo Capoccia, Dirk M. Maybauer, Marc O. Maybauer

Research output: Contribution to journalArticlepeer-review


Extracorporeal membrane oxygenation (ECMO) is a widely used technique to provide circulatory and/or respiratory support in critically ill patients. ECMO treatment usually necessitates systemic anticoagulation. Unfractionated Heparin (UFH) is a commonly used anticoagulant in patients on ECMO support. In situations where UFH is contraindicated, alternative anticoagulation strategies can be applied, such as the use of direct thrombin inhibitors (DTI). Bivalirudin and argatroban are the most widely used DTIs. In this report we give account of the current evidence regarding dosing, monitoring and complications associated with the use of these agents in ECMO dependent patients.

Original languageEnglish (US)
Pages (from-to)652-655
Number of pages4
JournalInternational Journal of Artificial Organs
Issue number7
StatePublished - Jul 2022


  • Anticoagulation
  • COVID-19
  • ECLS
  • ECMO
  • MCS
  • argatroban
  • bivalirudin
  • mechanical circulatory support

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering


Dive into the research topics of 'Direct Thrombin Inhibition in Extracorporeal Membrane Oxygenation'. Together they form a unique fingerprint.

Cite this